Table 1. Taxane-based therapy versus non-taxane-based therapy in subgroups: meta-analysis of disease-free survival (DFS).

	Trials	DFS		p value	Test of Heterogeneity
		HR	95% CI			I2	p
Docetaxel	20,21,22,24,25,27,30,33–37	0.83	0.77 to 0.90	0.000	22.85	43.1%	0.044
75 mg/m2	20,22,25,27,33,37	0.81	0.73 to 0.91	0.000	7.63	34.5%	0.178
100 mg/m2	21,24,30,34–36	0.84	0.76 to 0.94	0.000	14.98	53.3%	0.036
Paclitaxel	23,29,32,38,40–42	0.82	0.76 to 0.88	0.000	5.42	0.0%	0.770
Weekly sequential	29	0.77	0.62 to 0.95	0.016	.	.	.
Every 2 weeks	32,40	0.84	0.67 to 1.04	0.109	0.10	0.0%	0.752
Every 3 weeks	23,38,41,42	0.82	0.73 to 0.93	0.003	4.96	39.5%	0.175
Trials with N+ only	21,23,29,30,32,33,35,37,41,42	0.82	0.77 to 0.87	0.000	5.69	23.8%	0.080
Observation Period
Median Follow–up 5 years	34,35,37,38	0.73	0.64 to 0.83	0.000	5.36	25.3%	0.253
Median Follow–up >5 years	20–25,27,29,30,32,33,36,40–42	0.86	0.82 to 0.90	0.000	19.78	24.1%	0.181
Menopausal Status
Premenopausal	20,21,23,30,35,37	0.78	0.65 to 0.94	0.010	9.63	48.1%	0.086
Postmenopausal	20,21,23,30,35,37	0.78	0.68 to 0.90	0.001	5.47	8.5%	0.362
ER Status
ER+	20,21,22,24,27,29,30,35,37,40,41	0.83	0.76 to 0.90	0.000	13.74	27.2%	0.185
ER−	20,21,22,24,27,29,30,35,37,40,41	0.80	0.73 to 0.88	0.000	5.88	0.0%	0.826